Snapshot from Aug 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Kelun-Biotech SKB565 IND Approval
Tech clinical trial approval

Kelun-Biotech SKB565 IND Approval

Analysis based on 6 articles · First reported Jul 27, 2026 · Last updated Jul 27, 2026

Sentiment
40
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The approval of SKB565's IND application is a positive development for Kelun-Biotech, potentially enhancing its pipeline and market position in the ADC space. The news may boost investor confidence in the company's innovative capabilities and could lead to increased valuation.

biotechnology pharmaceutical
Event Summary

Sichuan Kelun-Biotech Biopharmaceutical announced on July 27, 2026 that it received a clinical trial notice from the United States — Center for Drug Evaluation and Research (CDE) of the China — National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for its novel dual-payload ADC drug, SKB565, for the treatment of advanced solid tumors. This marks the Company's first dual-payload ADC to enter the clinical stage. SKB565 is developed using the Company's proprietary OptiDC platform and features a dual-payload design delivering toxins and immunomodulators. In preclinical studies, SKB565 demonstrated excellent antitumor activity and safety. The advancement supports Kelun-Biotech's 'ADC + IO' strategy.

Key Actions
100 Sichuan Kelun-Biotech Biopharmaceutical received clinical trial notice
Entities Involved
priv
Sichuan Kelun-Biotech Biopharmaceutical
Kelun-Biotech is the central entity; the IND approval for SKB565 advances its pipeline and validates its ADC platform, potentially increasing its market value and competitive position.
Importance 100.0 Sentiment 60.0
govactor
United States — Center for Drug Evaluation and Research
The CDE, as part of NMPA, approved the IND application, playing a regulatory role in the event.
Importance 30.0 Sentiment 0.0
govactor
China — National Medical Products Administration
The NMPA, through its CDE, granted the clinical trial notice, enabling the trial to proceed.
Importance 30.0 Sentiment 0.0
stock
Sichuan Kelun Pharmaceutical
As the parent company of Kelun-Biotech, Sichuan Kelun Pharmaceutical may benefit indirectly from the positive development.
Importance 20.0 Sentiment 30.0
per
Michael Ge
Dr. Michael Ge, CEO of Kelun-Biotech, commented on the milestone, representing the company's leadership.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.